What Is Liraglutide?

Summary: Liraglutide is a once-daily GLP-1 receptor agonist injection that lowers blood sugar in type 2 diabetes (Victoza) and produces clinically meaningful weight loss (Saxenda), FDA approved since 2010.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Liraglutide is a daily injectable GLP-1 receptor agonist. It is sold under two brand names with two different label indications: Victoza treats type 2 diabetes and reduces cardiovascular risk, and Saxenda treats obesity. The active molecule is identical in both pens. The only thing that changes is the maximum dose ^[4].

It was the first GLP-1 medication approved for chronic weight management in the United States, and it remains one of the most studied drugs in this class.

The fast facts

How liraglutide works

Liraglutide is a modified version of the human GLP-1 hormone. Native GLP-1 is released by the gut after a meal and tells the pancreas to release insulin, slows gastric emptying, and signals satiety to the brain. Native GLP-1 also breaks down in minutes, which makes it useless as a drug.

Novo Nordisk solved that problem by attaching a fatty acid chain to the GLP-1 peptide. The modification lets liraglutide bind to albumin in the bloodstream, which protects it from enzymatic breakdown and stretches its half-life to roughly 13 hours ^[1]. That is long enough for one daily injection to maintain steady drug levels in the body.

Once liraglutide reaches the GLP-1 receptor, it does four things that matter for diabetes and weight:

1. Stimulates insulin release from pancreatic beta cells, but only when blood glucose is elevated. That glucose-dependent action is why GLP-1 agonists do not cause hypoglycemia on their own the way insulin and sulfonylureas can.
2. Suppresses glucagon, the hormone that tells the liver to release stored glucose. Less glucagon means less liver glucose dumping.
3. Slows gastric emptying. Food sits in the stomach longer, glucose enters the bloodstream more gradually, and you feel full sooner.
4. Acts on appetite centers in the hypothalamus to reduce hunger and food reward signaling.

The first two effects drive the blood sugar improvement. The last two drive the weight loss.

Victoza vs Saxenda: same drug, different jobs

The single most confusing thing about liraglutide is the two-brand setup. Here is the short version.

The chemistry is identical. If you put Victoza in a Saxenda pen and vice versa, the molecule does not know the difference. Insurance and the FDA do. You cannot prescribe Victoza for weight loss and bill it correctly, and Saxenda is not approved as monotherapy for blood sugar control even though it would work.

The dose ceiling explains why the brands exist. The diabetes trials capped at 1.8 mg because that is where the glycemic benefit plateaued. The obesity program (the SCALE trials) showed that pushing the dose to 3.0 mg added meaningful weight loss without adding much side effect risk for patients who tolerated the lower steps ^[3]. So Novo Nordisk priced and packaged the higher dose under a separate brand and ran it through a separate FDA pathway.

How long has Saxenda been around

Saxenda received FDA approval on December 23, 2014, which makes it the first GLP-1 receptor agonist approved for chronic weight management in the US. Victoza preceded it by almost five years, getting its diabetes approval on January 25, 2010 ^[4]. So if you are counting from the introduction of liraglutide as a molecule, the answer is 2010. If you are counting from when it was specifically labeled for weight loss, the answer is 2014.

That history matters because liraglutide has more long-term real-world safety data than any other GLP-1 used for obesity. Semaglutide (Wegovy) launched in 2021. Tirzepatide (Zepbound) launched in 2023. Liraglutide has been in human use for over a decade longer, with millions of patient-years on the market.

What does Saxenda look like

Saxenda ships as a multi-dose disposable pre-filled pen. The pen is off-white plastic with a dark gray dose selector at the bottom. It is roughly the size of a thick marker, about 6 inches long. Each pen contains 3 mL of liraglutide solution at 6 mg/mL, which delivers up to 18 mg of total drug over the life of the pen.

The pen has a dial mechanism, not a fixed-dose button. You twist the selector until your prescribed dose lines up with the marker arrow, attach a NovoFine needle, prime, then inject. The dose marks on Saxenda are 0.6, 1.2, 1.8, 2.4, and 3.0 mg, matching the weekly titration steps. You will not see milliliter or unit markings on the pen body. You see milligrams.

A Saxenda starter pack contains five pens, which is enough for the full 5-week titration if you stay on dose. Once you hit 3.0 mg daily as the maintenance dose, one pen lasts six days, and a 30-day supply requires five pens.

Liraglutide dosing schedule

Both brands start the same way and titrate gradually to manage gastrointestinal side effects.

Victoza for type 2 diabetes ^[1]:

• Week 1: 0.6 mg once daily
• Week 2 onward: 1.2 mg once daily
• Optional: 1.8 mg once daily if additional glycemic control is needed

The 0.6 mg dose is intended only to reduce nausea during the first week. It is not effective for blood sugar control on its own.

Saxenda for weight loss ^[2]:

• Week 1: 0.6 mg once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 onward: 3.0 mg once daily (maintenance)

If you cannot tolerate the next step, your prescriber may keep you at the current dose for an extra week before pushing forward. Children 12 and older who cannot tolerate 3.0 mg can stay at 2.4 mg as a maintenance dose.

You can inject at any time of day, with or without food. Pick a time you will remember and stay consistent. The injection site rotates between abdomen, thigh, and upper arm.

Liraglutide for weight loss: what the trials showed

The SCALE Obesity and Prediabetes trial is the pivotal study. It randomized 3,731 adults with obesity (BMI 30 or higher) or overweight with a weight-related comorbidity (BMI 27 or higher) to liraglutide 3.0 mg or placebo, both with diet and exercise counseling, over 56 weeks ^[3].

The headline numbers:

• Mean weight loss at 56 weeks: 8.0% with liraglutide, 2.6% with placebo
• 63.2% of liraglutide patients lost at least 5% of body weight, versus 27.1% on placebo
• 33.1% lost at least 10%, versus 10.6% on placebo

That is a real signal, but it is well below what newer drugs in the class produce. Semaglutide 2.4 mg (Wegovy) averages around 15% weight loss in the STEP trials. Tirzepatide 15 mg (Zepbound) averages around 20% in SURMOUNT-1. Liraglutide was the proof of concept that GLP-1 receptor agonists could drive double-digit weight loss. The follow-on molecules just do it better.

There are still reasons a prescriber picks liraglutide over the newer weekly options:

• Patients who cannot tolerate the longer half-life of weekly drugs sometimes do better on daily dosing because side effects clear faster between doses
• Wider insurance coverage than newer brands in some plans
• Generic availability is coming for the diabetes indication, which will affect price competition
• More than a decade of post-marketing safety data, including the LEADER cardiovascular outcomes trial of over 9,300 patients ^[5]

Liraglutide for type 2 diabetes

Victoza is FDA approved to improve glycemic control in adults and children 10 years and older with type 2 diabetes ^[1]. It is also approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, based on the LEADER trial.

LEADER enrolled 9,340 patients with type 2 diabetes at high cardiovascular risk and followed them for a median of 3.8 years ^[5]. Liraglutide reduced the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 13% relative to placebo. Cardiovascular death alone dropped 22%. That outcome benefit is why Victoza has a cardiovascular risk reduction indication on the label, which puts it in a small group of diabetes drugs proven to extend life expectancy in high-risk patients.

A generic version of liraglutide injection (1.8 mg) for type 2 diabetes was approved by the FDA on December 23, 2024 ^[4]. That generic is not approved for weight loss. Only the brand-name Saxenda is approved at the 3.0 mg dose.

Side effects

The side effect profile of liraglutide is the GLP-1 class profile ^[4]:

Most common (more than 5% of patients in clinical trials):

• Nausea
• Diarrhea
• Vomiting
• Decreased appetite
• Constipation
• Headache
• Indigestion
• Fatigue
• Dizziness
• Stomach pain
• Injection site reaction

Most of these are dose-related and improve after the first few weeks of titration. Nausea is the dominant complaint, and it is the reason for the slow stepped-up dosing schedule. Patients who skip steps or push too fast almost always quit early.

Serious risks listed in the FDA label include pancreatitis, gallbladder disease, kidney injury from dehydration, severe allergic reactions, and increased heart rate. Patients on liraglutide should not use any other GLP-1 receptor agonist at the same time, including Ozempic, Wegovy, Trulicity, Mounjaro, Zepbound, Byetta, or Rybelsus ^[4].

Common myths and clarifications

A surprising amount of confusion exists about what liraglutide actually is. The short answers:

• Is Saxenda a narcotic? No. Liraglutide is not a controlled substance. It has no addiction potential, no DEA scheduling, and no abuse profile. It is a peptide hormone analog.
• Is Saxenda a steroid? No. Steroids are lipid-based molecules with a specific four-ring structure. Liraglutide is a 31-amino-acid peptide. The chemistry has nothing in common.
• Is Saxenda a stimulant? No. It does not act on dopamine, norepinephrine, or adrenergic receptors. Saxenda reduces appetite by acting on GLP-1 receptors in the gut and brain, not by speeding up the nervous system. People do not get jittery, sleepless, or wired on it the way they do on phentermine or amphetamine-based weight loss drugs.
• Is pregnenolone in Saxenda? No. Pregnenolone is a steroid hormone precursor sometimes sold as a supplement. It is not an ingredient in Saxenda. The active ingredient is liraglutide, and the inactive ingredients are disodium phosphate dihydrate, propylene glycol, phenol, and water for injection.

If someone is selling you "liraglutide" with extra ingredients like pregnenolone, hormones, or stimulants, that is not FDA-approved Saxenda or Victoza. It is a compounded or counterfeit product, and the safety profile is not the same.

Who should not take liraglutide

The contraindications on the FDA label are clear ^[1][2]:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Known hypersensitivity to liraglutide or any of the pen ingredients
• Pregnancy (Saxenda; risk-benefit decision for Victoza)

Use caution and discuss carefully with your prescriber if you have:

• History of pancreatitis
• Severe gastroparesis or other significant GI motility disorders
• Severe kidney disease
• Type 1 diabetes (liraglutide is not approved for type 1 and does not replace insulin)
• Active gallbladder disease

How liraglutide compares to other GLP-1 drugs

For weight loss specifically, liraglutide produces less average weight loss than semaglutide or tirzepatide. The daily injection burden is also a factor for some patients. The case for liraglutide today is usually one of three things: insurance coverage favors it, the patient cannot tolerate weekly drugs, or generic availability brings the cost down sharply once it reaches the obesity indication.

Frequently asked questions

What is liraglutide used for?

Liraglutide is used to improve blood sugar in type 2 diabetes (Victoza), reduce cardiovascular risk in adults with type 2 diabetes and established heart disease (Victoza), and treat obesity in adults and adolescents 12 and older (Saxenda).

Is liraglutide the same as Ozempic?

No. Liraglutide is a daily GLP-1 agonist. Ozempic is semaglutide, a weekly GLP-1 agonist made by the same company. Both work on the GLP-1 receptor, but semaglutide is a different molecule with stronger weight loss data.

How much weight do people lose on Saxenda?

In the SCALE trial, the average weight loss at 56 weeks on liraglutide 3.0 mg plus lifestyle changes was 8.0%, compared to 2.6% on placebo. About 63% of patients lost at least 5% of body weight.

How long does it take Saxenda to work?

Appetite suppression often begins within the first one to two weeks. Meaningful weight loss usually shows by 8 to 12 weeks. The FDA label recommends discontinuing Saxenda if a patient has not lost at least 4% of body weight at 16 weeks on the full dose.

Does Saxenda need to be refrigerated?

Yes before first use. After first use a pen can stay at room temperature (up to 86 F) or in the fridge for up to 30 days, then it must be discarded.

Can I switch from Saxenda to Wegovy or vice versa?

Yes, with prescriber guidance. The starting dose of the new drug is typically the standard titration starting dose, not the dose that matches your current liraglutide level. Do not take both at the same time.

Is there a generic liraglutide?

A generic liraglutide injection was FDA approved on December 23, 2024, for type 2 diabetes only. The 3.0 mg dose used in Saxenda for weight loss does not yet have an approved generic.

Can liraglutide cause low blood sugar?

Liraglutide alone rarely causes hypoglycemia because its insulin effect is glucose-dependent. The risk rises sharply when liraglutide is combined with insulin or sulfonylureas, in which case those drug doses may need to be reduced.

Is liraglutide safe long term?

Liraglutide has the longest real-world track record of any GLP-1 used for weight loss, with FDA approval since 2010 for diabetes. The LEADER cardiovascular trial followed patients for nearly four years and showed a mortality benefit. Long-term safety remains under post-marketing surveillance for thyroid risk.

How do I store Saxenda after first use?

Store at room temperature (up to 86 F) or in the refrigerator, never freeze, and discard 30 days after the first injection regardless of remaining drug.

Bottom line

Liraglutide is the original prescription GLP-1 receptor agonist for both diabetes and obesity. It works, it has the deepest safety dataset in the class, and it is dosed daily. Newer weekly drugs produce more weight loss on average, so most new prescriptions for obesity now go to semaglutide or tirzepatide. Liraglutide still earns its place when daily dosing fits a patient better, when insurance dictates the choice, or when a prescriber wants a molecule with over a decade of post-marketing experience behind it.